Moroccan Antibiotic Fix Earns International Science Prize
OLIPEN pairs an existing antibiotic with a natural resistance breaker and is already approved in Morocco.
Updated on Nov. 7, 2026 in Life Sciences

Live Poll
Do you trust new antibiotic treatments to be safe and effective for patients?
Adnane Remmal, a professor at Sidi Mohamed Ben Abdellah University in Fez, Morocco, received the UNESCO-Equatorial Guinea International Prize for Research in the Life Sciences for his work on antibiotic resistance. The award, shared among three scientists with a combined prize of $300,000, was presented Friday evening in Paris. The underlying approach is already in use: OLIPEN, the antibiotic Remmal developed, is approved for clinical use in Morocco.
Why it matters
Antibiotic resistance is one of the major public health challenges worldwide, and Remmal's strategy addresses it by restoring the effectiveness of existing antibiotics rather than waiting for entirely new drugs. The recognition signals institutional momentum behind resistance-breaking approaches, which could reduce the cost and time needed to develop new treatments.
The approach pairs a conventional antibiotic with a natural molecule that acts as a resistance breaker, restoring activity against bacteria that have become resistant to the antibiotic alone. The reported benefit to hundreds of thousands of patients in Morocco is Remmal's own account, and the source offers no independent trial figures or resistance-reduction percentages to verify it.
The players
Adnane Remmal
A professor at Sidi Mohamed Ben Abdellah University in Fez, Morocco, known for developing OLIPEN and natural alternatives to antibiotics for livestock.
Nancy Yuk-yu Ip
A Hong Kong-based researcher honored for work on brain mechanisms and Alzheimer's disease.
Carlos Martín Montañés
A researcher at the University of Zaragoza honored for the clinical development of a live attenuated tuberculosis vaccine.
The details
Antibiotic resistance occurs when bacteria evolve to survive drugs that once killed them, and it erodes the usefulness of medicines already in hand. Remmal's approach, embodied in OLIPEN, combines a conventional antibiotic with a component derived from essential oils that works as a resistance breaker, reviving the antibiotic's effect rather than replacing it. Remmal has also developed natural alternatives to antibiotics for livestock farming, extending the same logic to animal agriculture. The source does not describe the precise chemistry of the essential-oil component.
Timeline
The award was presented on Friday evening, November 6, 2026, in Paris.
The Tech Race
The prize sits alongside the UNESCO-Equatorial Guinea life sciences award's recognition of tuberculosis vaccine development and Alzheimer's research, showing the prize spanning infectious disease and neurology. Remmal's OLIPEN is distinct in being an approved, deployed product, while much of the surrounding research on resistance remains at the level of recognized science rather than marketed treatments.
OLIPEN is already approved for clinical use in Morocco, so patients there are the ones currently exposed to the combined approach. Availability outside Morocco, pricing, and regulatory timelines in other countries are not stated in the source.
The takeaway
Watch whether independent clinical data on OLIPEN emerges and whether its approval extends beyond Morocco, since that will show whether resistance-breaking combinations can scale as a model. The trajectory to track is whether institutional recognition like this translates into measured reductions in treatment failure.
Further reading
For the broader research context, explore our Life Sciences coverage.
Live Poll
Do you trust new antibiotic treatments to be safe and effective for patients?


